This is lengthy, but please read.  Lots of info here.  Chronically infected people need to carefully weigh vaccinations as their immune systems are already compromised.  Every person I know with MSIDS who got a vaccination suffered relapse.

12/10/2016 | 09:13am CET

(GlobeNewswire) – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines, today announced that its vaccine candidate VLA15 against Lyme disease is now progressing into clinical testing (Phase I) following the Investigational New Drug application (IND) clearance from the Food & Drug Administration (FDA) and the approval of the Clinical Trial Application (CTA) in Europe (Belgium).
Currently, there is no licensed vaccine available to protect humans against Lyme disease, a multi systemic tick-transmitted infection that can cause serious health problems and disabilities. Each year, an estimated 300,000 Americans and 85,000 Europeans develop Lyme disease and according to the CDC (Centers for Disease Control and Prevention), it is the fastest growing vector-borne infectious disease in the United States.
Valneva is developing a new hexavalent, protein subunit-based vaccine targeting the Outer Surface Protein A (OspA) of Borrelia. OspA is, one of the most dominant proteins expressed by the bacteria when present in a tick. Pre-clinical data showed that Valneva`s vaccine candidate can provide protection against the majority of Borrelia species pathogenic for humans[1].
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, commented, “We are very pleased to be able to advance our Lyme vaccine candidate which is intended to address such an important unmet medical need. We are committed to finding ways to accelerate the clinical development path to licensure, given that we are conducting the only active vaccine program in the industry.”
Valneva`s Phase I trial VLA15-101 is being conducted at two sites – one in the U.S. and one in Europe (Belgium) and will enroll 180 subjects, aged 18-40 years. The primary objective of the single-blind, partially randomized, dose escalation study will be to evaluate the product candidate`s safety and tolerability. Immunogenicity, measured by observing IgG antibodies specific against six OspA serotypes, will also be monitored for different dose groups and formulations at different time-points.

Investor Meeting and Live Webcast in New York, December 12th, 12pm Eastern Time.
Considering the strong interest shown on the disease by investors, shareholders and the general public, Valneva is hosting a conference on Lyme disease in New York on December 12, 2016 to provide more detailed information on the disease and the opportunity to develop a vaccine. The conference will be co-presented by Prof. Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania, and Valneva`s Lyme R&D experts led by CEO Thomas Lingelbach. To register for the conference, please visit Valneva`s website:

Valneva SE (Euronext Paris: VLA:EPA) is hosting a webcasted Key Opinion Leader Lunch on Developing a Vaccine for Lyme Disease TODAY, Monday, December 12, 2016, from 12:00-1:30 pm ET.
A live webcast and subsequent replay of the event will be available at: If you would like to ask a question during the live Q&A, please submit your request via email to
A Q&A session with the featured experts and management will follow the presentations.

About Valneva SE
Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva`s portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis and DUKORAL indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company`s value proposition and include vaccines being developed using Valneva`s innovative and validated technology platforms (EB66 vaccine production cell line, IC31 adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at
Laetitia Bachelot-Fontaine Teresa Pinzolits
Head of Investor RelationsCommunications Specialist
& Corporate CommunicationsT +43-1-206 20-1116
T +02-28-07-14-19M +43-676-84 55 67 357
M +33 (0)6 4516
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
(c) 2016 Provided by SyndiGate Media Inc. (, source Middle East & North African Newspapers

***Please know that the first Lyme vaccine, LYMErix, caused many folks to develop Chronic Lyme.

The CDC Fraud with vaccines and lyme (OspA) connection:

“The LYMEerix vaccine was manufactured with ‘outer surface protein A’ (OspA). OspA is fungal and therefore has an immunosuppressive effect – causing post-sepsis syndrome. People injected with this vaccine were effected similarly to those bitten by a tick -which injects spirochetes (toxic fungi). Ironically, this vaccine was making people sick with the exact thing it was supposed to prevent!
The LYMErix vaccine gave people the same disease we know of as chronic neurologic Lyme, so then what is the disease? What is OspA?
The LYMErix vaccine was patented by the U.S. Centers for Disease Control and prevention (CDC). The synthetic OspA injected into subjects in the trial for the vaccine were getting sick. They were injected with a fungal type antigen which is toxic to humans.
LYMErix was pulled off the market when this fact was revealed to the FDA. But was anyone prosecuted like with the NECC scandal? Did anyone go to jail for racketeering? Was a fund set up for the victims?
Petition for a Congressional Investigation
It’s time to hold the CDC, Merck, Yale, IDSA (and others) responsible for the lives they have destroyed. Carl Tuttle started a petition with over 34k signatures so far – “Calling for a Congressional investigation of the CDC, IDSA and ALDF””

LYMERix Vaccine Victim’s Stories – FDA:

Please read Dr. Sticker’s (a prominent LLMD) comments on the vaccine:

Raphael Stricker2017 Feb 08 1:33 p.m.edited

Another Lyme OspA Vaccine Whitewash

The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccinees.

References 1. Stricker RB (2008) Lymerix® risks revisited. Microbe 3: 1–2. 2. Marks DH (2011) Neurological complications of vaccination with outer surface protein A (OspA). Int J Risk Saf Med. 23: 89–96. 3. Stricker RB, Johnson L (2014) Lyme disease vaccination: safety first. Lancet Infect Dis. 14(1):12.


If you want to know more about vaccines in general: